Protara Therapeutics, Inc. — Director's Dealing 2022

Jul 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2022-07-15

Reporting Person: Davis Blaine (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-15	Common Stock	F	5081	$3.13	Disposed	20662	Direct

Footnotes

F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022.